Invasive Group A Beta-Haemolytic Streptococcal Disease
4
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by No Intervention
Research Leaders
20 sponsors active, led by Gregorio Marañón Hospital
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Severe Group A Streptococcus Infections in Paris, France, 2018-2023
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Paediatric European Group A Streptococcal United Study.
Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)
Research Network
Common Treatments
- No Intervention2
- Collection Of Data From The Patients Medical File1
- Linezolid1
- Clindamycin1
Active Sponsors
- Gregorio Marañón Hospital1
- Hospital Clinico Universitario de Santiago1
- Tampere University Hospital1
- Maasstad Hospital1
- Wroclaw Medical University1
Top Investigators
Emory University
Assistance Publique - Hôpitaux de Paris
Tampere University Hospital
Assistance Publique - Hôpitaux de Paris
Related Conditions
- Streptococcal Toxic Shock Syndrome1
- Infection Bacterial1
- Necrotizing Soft Tissue Infection1
- Infection Bloodstream1
- Streptococcal Sepsis1